New Drug Combination Increases Overall Survival in Patients with PIK3CA-Mutated Advanced Breast Cancer
A recently completed phase 3 clinical trial, conducted by researchers at Mass General Brigham and collaborators, shows that combining inavolisib with palbociclib and fulvestrant improves overall survival for patients with advanced PIK3CA-mutated breast cancer.